Groupon (GRPN) Exceeds Market Returns: Some Facts to Consider

Groupon (GRPN) recently saw a 2.24% daily gain to $23.25, outperforming the S&P 500, yet it recorded a 12.87% loss over the past month. While the company is projected to report a 96.97% year-over-year EPS decline to $0.01 for its upcoming quarter, full-year estimates indicate a robust 152.98% EPS growth to $0.8 on $504.5 million in revenue. GRPN holds a Zacks Rank #1 (Strong Buy) and trades at a premium Forward P/E of 28.42, exceeding its industry average of 22.36, within an industry ranked in the top 29% by Zacks.

Analysis

Groupon (GRPN) presents a bifurcated outlook, characterized by near-term operational weakness but a strong long-term recovery forecast. While the stock's recent +2.24% daily gain outpaced the market, it follows a significant 12.87% decline over the past month, where it underperformed its sector and the S&P 500. The upcoming earnings report is a pivotal event, with consensus estimates pointing to a severe 96.97% year-over-year decline in quarterly EPS to just $0.01, even as revenues are projected to grow 6.47% to $121.88 million. This stark quarterly projection contrasts sharply with the full-year outlook, where analysts expect a robust 152.98% surge in EPS to $0.80 on a modest 2.42% revenue increase. Despite stagnant consensus EPS estimates over the last month, the stock maintains a Zacks Rank #1 (Strong Buy), indicating underlying optimism from the rating model. This bullishness is paired with a premium valuation, as GRPN's forward P/E ratio of 28.42 is elevated compared to its industry's average of 22.36, suggesting high expectations are already priced in.

Key Decisions for Investors

• Investors should closely monitor the upcoming earnings release for any deviation from the projected 96.97% EPS decline and, more critically, for management's confirmation of the strong full-year guidance which projects 153% EPS growth.
• Given the stock's premium forward P/E of 28.42 relative to its industry, it is crucial to weigh the bullish Zacks #1 rank against the risk that the anticipated full-year earnings recovery is already priced in, increasing downside risk if guidance is missed.
• Consider the recent 12.87% monthly share price decline as a sign of market skepticism regarding the company's ability to transition from a severe quarterly profit drop to a significant full-year recovery, suggesting a cautious stance may be warranted until the path to profitability is clearer.